We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Collaboration to Develop Sepsis Diagnostics

By Labmedica staff writers
Posted on 23 Oct 2005
A joint agreement for the evaluation and potential commercialization of sepsis markers has been announced by SIRS-Lab GmbH (Jena, Germany) and Biosite Inc. More...
(San Diego, CA, USA). Financial terms were not disclosed.

Under the agreement, SIRS-Lab will provide access to selected biomarkers for sepsis. Biosite will make antibodies to those selected targets, using its proprietary antibody-
development process. This process combines the immunization of mice and phage display to generate highly diverse libraries of antibodies with high affinity and low cross-reactivity, called Omniclonal antibodies. These antibodies will then be used to generate assays for the measurement of the selected biomarker targets in blood samples. Validated biomarkers will be assessed for their commercial potential, with high-value markers being added to Biosite's product-development process.

"This agreement combines the strengths of both companies: Biosite's proven antibody development and commercialization process for diagnostic products with our expertise in molecular medicine concerning inflammatory diseases,” noted Dr. Stefan Rubwurm, CEO of SIRS-Lab.

SIRS-Lab is a research-driven diagnostics company focused on the identification and development of biomarkers for the development of diagnostic systems that can identify inflammatory-immunologic host responses or bacterial causes of infection. Biosite commercializes proteomics discoveries that advance medical diagnosis. The company's Triage diagnostics are used in more than 50 international markets.





Related Links:
SIRS-Lab
Biosite

Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic CLIA Analyzer
Shine i9000
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.